1
|
Huters AD, Stambuli J, Klix RC, Matulenko MA, Chan VS, Simanis J, Hill DR, Reddy RE, Towne TB, Bellettini JR, Kotecki BJ, Cardinal-David B, Ji J, Voight EA, Shou M, Balaraman S, Ashok A, Ghosh S. Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease. J Org Chem 2021; 87:1986-1995. [PMID: 34280307 DOI: 10.1021/acs.joc.1c00905] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Foslevodopa (FLD, levodopa 4'-monophosphate, 3) and foscarbidopa (FCD, carbidopa 4'-monophosphate, 4) were identified as water-soluble prodrugs of levodopa (LD, 1) and carbidopa (CD, 2), respectively, which are useful for the treatment of Parkinson's disease. Herein, we describe asymmetric syntheses of FLD (3) and FCD (4) drug substances and their manufacture at pilot scale. The synthesis of FLD (3) employs a Horner-Wadsworth-Emmons olefination reaction followed by enantioselective hydrogenation of the double bond as key steps to introduce the α-amino acid moiety with the desired stereochemistry. The synthesis of FCD (4) features a Mizoroki-Heck reaction followed by enantioselective hydrazination to install the quaternary chiral center bearing a hydrazine moiety.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Selvakumar Balaraman
- Anthem Biosciences, No. 49 Canara Bank Road, Bommasandra Industrial Area, Bangalore 560 099, Karnataka, India
| | - Abhishek Ashok
- Anthem Biosciences, No. 49 Canara Bank Road, Bommasandra Industrial Area, Bangalore 560 099, Karnataka, India
| | - Soma Ghosh
- Anthem Biosciences, No. 49 Canara Bank Road, Bommasandra Industrial Area, Bangalore 560 099, Karnataka, India
| |
Collapse
|
2
|
Voight EA, Greszler SN, Hartung J, Ji J, Klix RC, Randolph JT, Shelat BH, Waters JE, DeGoey DA. Desymmetrization of pibrentasvir for efficient prodrug synthesis. Chem Sci 2021; 12:10076-10082. [PMID: 34349971 PMCID: PMC8317637 DOI: 10.1039/d1sc02396a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 06/28/2021] [Indexed: 12/15/2022] Open
Abstract
A novel and practical desymmetrization tactic is described to access a new class of pibrentasvir prodrugs. The homotopic benzimidazoles of pibrentasvir (PIB) are differentiated via a one-pot di-Boc/mono-de-Boc selective N-Boc protection and formaldehyde adduct formation sequence, both enabled by crystallization-induced selectivity. The first step represents the only known application of the Horeau principle of statistical amplification for C2-symmetric polyheterocycle regioselective functionalization. The resulting versatile intermediate is employed in the high-yielding preparation of several pibrentasvir prodrug candidates. Horeau principle statistical amplification and solubility-driven selectivities allow C2-desymmetrization of pibrentasvir without typically required internal functionalization or steric proximity effects.![]()
Collapse
Affiliation(s)
- Eric A Voight
- Drug Discovery Science & Technology, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| | - Stephen N Greszler
- Drug Discovery Science & Technology, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| | - John Hartung
- Process Research and Development, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| | - Jianguo Ji
- Process Research and Development, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| | - Russell C Klix
- Process Research and Development, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| | - John T Randolph
- Drug Discovery Science & Technology, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| | - Bhadra H Shelat
- Process Research and Development, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| | - Jan E Waters
- Drug Discovery Science & Technology, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| | - David A DeGoey
- Drug Discovery Science & Technology, AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-1802 USA
| |
Collapse
|
3
|
Salem AH, Tao ZF, Bueno OF, Chen J, Chen S, Edalji R, Elmore SW, Fournier KM, Harper KC, Hong R, Jenkins GJ, Ji J, Judge RA, Kalvass JC, Klix RC, Ku YY, Leverson JD, Marks RA, Marsh KC, Menon RM, Park CH, Phillips DC, Pu YM, Rosenberg SH, Sanzgiri YD, Sheikh AY, Shi Y, Stolarik D, Suleiman AA, Wang X, Zhang GGZ, Catron ND, Souers AJ. Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers. Mol Cancer Ther 2021; 20:999-1008. [PMID: 33785651 DOI: 10.1158/1535-7163.mct-21-0077] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 02/15/2021] [Accepted: 03/15/2021] [Indexed: 11/16/2022]
Abstract
Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other blood-related cancers. Reflecting the large and hydrophobic BH3-binding groove within BCL-2, venetoclax has significantly higher molecular weight and lipophilicity than most orally administered drugs, along with negligible water solubility. Although a technology-enabled formulation successfully achieves oral absorption in humans, venetoclax tablets have limited drug loading and therefore can present a substantial pill burden for patients in high-dose indications. We therefore generated a phosphate prodrug (3, ABBV-167) that confers significantly increased water solubility to venetoclax and, upon oral administration to healthy volunteers either as a solution or high drug-load immediate release tablet, extensively converts to the parent drug. Additionally, ABBV-167 demonstrated a lower food effect with respect to venetoclax tablets. These data indicate that beyond-rule-of-5 molecules can be successfully delivered to humans via a solubility-enhancing prodrug moiety to afford robust exposures of the parent drug following oral dosing.
Collapse
Affiliation(s)
- Ahmed Hamed Salem
- AbbVie, Inc., North Chicago, Illinois.,Ain Shams University, Cairo, Egypt
| | | | | | - Jie Chen
- AbbVie, Inc., North Chicago, Illinois
| | | | | | | | | | | | | | | | | | | | | | | | - Yi-Yin Ku
- AbbVie, Inc., North Chicago, Illinois
| | | | | | | | | | | | | | | | | | | | | | - Yi Shi
- AbbVie, Inc., North Chicago, Illinois
| | | | - Ahmed A Suleiman
- AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany
| | - Xilu Wang
- AbbVie, Inc., North Chicago, Illinois
| | | | | | | |
Collapse
|
4
|
Hartung J, Greszler SN, Klix RC, Kallemeyn JM. Development of an Enantioselective [3 + 2] Cycloaddition To Synthesize the Pyrrolidine Core of ABBV-3221 on Multikilogram Scale. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00292] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- John Hartung
- Process Research and Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Stephen N. Greszler
- Discovery Chemistry and Technology, AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Russell C. Klix
- Process Research and Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| | - Jeffrey M. Kallemeyn
- Process Research and Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
| |
Collapse
|